Mikhail Silk

Dr. Mikhail Silk


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2024 in Livers
Verified
Journal Article
Open access
PDF file
JLJonah Levine
Jonah Levine
AHAlyssar Habib
Alyssar Habib
MSMikhail Silk
Mikhail Silk
GSGreg Sacks
Greg Sacks
RWRafael Winograd
Rafael Winograd
BHBrock Hewitt
Brock Hewitt
The liver is a common site for metastatic disease. In select patients with isolated liver metastases, surgical resection improves survival and may be potentially curative in patients with favorable “tumor biology”. However, when surgical resection is not feasible, liver-directed therapies (LDTs) can also improve outcomes, including survival, in the appropriate clinical situations. LDTs, including hepatic artery infusion, radioembolization, radiation, and ablation techniques, such as thermal ablation and histotripsy, offer local control and potential systemic effects, including the abscopal effect. The abscopal effect occurs when nontargeted, nontreated tumors regress following localized therapy to other tumors. Preclinical and clinical studies suggest that antigen-induced upregulation of key immune regulators plays a central role in this process. Unfortunately, clinical reports of the abscopal effect following LDT are exceedingly rare. However, histotripsy, a noninvasive, nonionizing, and nonthermal ablation technique, may induce an abscopal effect more frequently and robustly than other LDTs. Histotripsy enhances tumor immunogenicity through precise acoustic cavitation that better preserves the local tissue architecture while increasing antigen release, resulting in a robust local and systemic immune response. Ongoing trials are investigating these immunogenic mechanisms and the ability to generate an abscopal effect more reliably with adjuncts such as checkpoint inhibitors. This work has significant implications regarding the management of patients with liver metastasis.

28 October 2026 in Lymphatics
Verified
Journal Article
Open access
PDF file
AVAndre Constantin Vogel
Andre Constantin Vogel
DFDaniel Freedman
Daniel Freedman
PCPatrick Carey
Patrick Carey
ASAbhay Srinivasan
Abhay Srinivasan
MSMikhail Silk
Mikhail Silk
DKDhara Kinariwala
Dhara Kinariwala
Acquired lymphatic flow disorders include chylothorax, plastic bronchitis, chylous ascites, protein-losing enteropathy, and post-operative lymphocele. These heterogenous clinical entities share common mechanisms and pathophysiology: disruption to normal antegrade flow of lymphatic fluid. Advances in imaging and interventional techniques have improved physicians’ ability to diagnose and treat these diseases. Workup with computed tomography, heavily T2-weighted MRI, and dynamic contrast-enhanced magnetic resonance lymphangiography can elucidate etiologies and provide targets for intervention. Initial management consists of very-low fat diets, medium chain triglyceride supplementation, and pharmacologic therapy with somatostatin analogs. If conservative management fails, interventions like thoracic duct embolization, thoracic duct stent-grafting and decompression, transjugular intrahepatic porto-systemic shunting, and lymphatic channel embolization offer novel, minimally invasive options, with surgery reserved for refractory cases. Future investigations will establish long-term outcomes after thoracic duct embolization, elucidate the relative benefit of thoracic duct embolization versus stent-grafting, and establish standardized treatment algorithms for post-operative lymphocele. In this review, we discuss the etiologies, workup, diagnosis, and management of acquired lymphatic flow disorders.